Daniel Tassé

Chief Executive Officer, Dbv

Search every verified Daniel Tassé interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Daniel Tassé, CEO of DBV Technologies, stated during the company’s Q2 2026 earnings call that the company is working to transform into a commercial organization in anticipation of potential FDA approval of the Viaskin peanut patch for children aged 4 to 7. He noted that the company plans to request priority review for its Biologics License Application, citing the platform’s breakthrough designation, and outlined a timeline of up to 60 days for the FDA to accept the filing and decide on priority review status, which would then entail a six-month review. Tassé also said the company is funded into the third quarter of 2027 to support operations and commercial preparedness, including investments in core functions needed for a potential launch. He described the daily burden of food allergies on families and expressed confidence in the company’s technology and science to make a difference.